Unicycive Therapeutics (UNCY) Stock Analysis

What Unicycive Therapeutics does

Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.

Key metrics

ETFs linked to UNCY

Broad-market and Healthcare sector ETFs an investor holding Unicycive Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how UNCY fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Unicycive Therapeutics?

Unicycive Therapeutics trades under the ticker UNCY on NASDAQ.

Which exchange is UNCY listed on?

UNCY is listed on NASDAQ.

What sector does Unicycive Therapeutics operate in?

Unicycive Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze UNCY in a portfolio?

PortView shows UNCY's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.